228 related articles for article (PubMed ID: 22194853)
1. Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/µL and virologic suppression: a systematic review.
Costiniuk CT; Fergusson DA; Doucette S; Angel JB
PLoS One; 2011; 6(12):e28570. PubMed ID: 22194853
[TBL] [Abstract][Full Text] [Related]
2. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
[TBL] [Abstract][Full Text] [Related]
3. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed.
D'Egidio GE; Kravcik S; Cooper CL; Cameron DW; Fergusson DA; Angel JB
AIDS; 2007 Aug; 21(13):1711-5. PubMed ID: 17690568
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.
Weverling GJ; Mocroft A; Ledergerber B; Kirk O; Gonzáles-Lahoz J; d'Arminio Monforte A; Proenca R; Phillips AN; Lundgren JD; Reiss P
Lancet; 1999 Apr; 353(9161):1293-8. PubMed ID: 10218526
[TBL] [Abstract][Full Text] [Related]
5. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL.
Atkinson A; Miro JM; Mocroft A; Reiss P; Kirk O; Morlat P; Ghosn J; Stephan C; Mussini C; Antoniadou A; Doerholt K; Girardi E; De Wit S; Kraus D; Zwahlen M; Furrer H;
J Int AIDS Soc; 2021 Jun; 24(6):e25726. PubMed ID: 34118121
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy.
Schneider MM; Borleffs JC; Stolk RP; Jaspers CA; Hoepelman AI
Lancet; 1999 Jan; 353(9148):201-3. PubMed ID: 9923876
[TBL] [Abstract][Full Text] [Related]
7. Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy.
Cheng CY; Chen MY; Hsieh SM; Sheng WH; Sun HY; Lo YC; Liu WC; Hung CC
BMC Infect Dis; 2010 May; 10():126. PubMed ID: 20492660
[TBL] [Abstract][Full Text] [Related]
8. Pneumocystis carinii pneumonia recurrence in HIV patients on highly active antiretroviral therapy: secondary prophylaxis.
Abgrall S; Matheron S; Le Moing V; Dupont C; Costagliola D;
J Acquir Immune Defic Syndr; 2001 Feb; 26(2):151-8. PubMed ID: 11242182
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.
Goldie SJ; Kaplan JE; Losina E; Weinstein MC; Paltiel AD; Seage GR; Craven DE; Kimmel AD; Zhang H; Cohen CJ; Freedberg KA
Arch Intern Med; 2002 Apr; 162(8):921-8. PubMed ID: 11966344
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators.
Yangco BG; Von Bargen JC; Moorman AC; Holmberg SD
Ann Intern Med; 2000 Feb; 132(3):201-5. PubMed ID: 10651600
[TBL] [Abstract][Full Text] [Related]
12. Pneumocystis jirovecii prophylaxis discontinuation based upon total lymphocyte count in HIV-infected adults treated with antiretroviral therapy.
Cheung C; Shuter J
Int J STD AIDS; 2010 Jun; 21(6):406-9. PubMed ID: 20606220
[TBL] [Abstract][Full Text] [Related]
13. Withdrawal of Pneumocystis jirovecii prophylaxis in HIV-infected children under highly active antiretroviral therapy.
Urschel S; Ramos J; Mellado M; Giaquinto C; Verweel G; Schuster T; Niehues T; Belohradsky B; Wintergerst U;
AIDS; 2005 Dec; 19(18):2103-8. PubMed ID: 16284459
[TBL] [Abstract][Full Text] [Related]
14. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group.
Mussini C; Pezzotti P; Antinori A; Borghi V; Monforte Ad; Govoni A; De Luca A; Ammassari A; Mongiardo N; Cerri MC; Bedini A; Beltrami C; Ursitti MA; Bini T; Cossarizza A; Esposito R;
Clin Infect Dis; 2003 Mar; 36(5):645-51. PubMed ID: 12594647
[TBL] [Abstract][Full Text] [Related]
16. Discontinuing Pneumocystis jirovecii Pneumonia Prophylaxis in HIV-Infected Patients With a CD4 Cell Count <200 cells/mm3.
Sidhu VK; Foisy MM; Hughes CA
Ann Pharmacother; 2015 Dec; 49(12):1343-8. PubMed ID: 26358129
[TBL] [Abstract][Full Text] [Related]
17. A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 x 106 /l.
Koletar SL; Heald AE; Finkelstein D; Hafner R; Currier JS; McCutchan JA; Vallee M; Torriani FJ; Powderly WG; Fass RJ; Murphy RL;
AIDS; 2001 Aug; 15(12):1509-15. PubMed ID: 11504983
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.
Simonds RJ; Lindegren ML; Thomas P; Hanson D; Caldwell B; Scott G; Rogers M
N Engl J Med; 1995 Mar; 332(12):786-90. PubMed ID: 7862183
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Absolute CD4 Count and Percentage Discordance on Pneumocystis Jirovecii Pneumonia Prophylaxis in HIV-Infected Patients.
Anyimadu H; Pingili C; Sivapalan V; Hirsch-Moverman Y; Mannheimer S
J Int Assoc Provid AIDS Care; 2018; 17():2325958218759199. PubMed ID: 29534652
[TBL] [Abstract][Full Text] [Related]
20. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.
Jones JL; Hanson DL; Dworkin MS; Alderton DL; Fleming PL; Kaplan JE; Ward J
MMWR CDC Surveill Summ; 1999 Apr; 48(2):1-22. PubMed ID: 12412613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
